Adherex to present data from phase 1b study of ADH-1 in cancer at oncology meeting

By Lisa Kerner

Erie, Pa., May 3 - Adherex Technologies Inc. said it concluded the phase 1b component of its phase 1b/2 ADH-1 trial in Europe. Data will be presented at the 2006 American Society of Clinical Oncology Annual meeting in Atlanta.

In addition, Adherex has started the expanded accrual restricted to lung and ovarian cancers.

The study, examining a weekly dosing schedule of ADH-1, will now enroll about 20 patients at the maximum studied dose of 2,400 mg/m2 with N-cadherin positive non-small cell lung cancer and ovarian cancer, according to a company news release.

Adherex is also studying ADH-1 as a single agent in a phase 2 trial at six centers in Canada. This trial is examining a weekly dosing schedule of 600 mg/m2 of ADH-1 in patients with one of five N-cadherin positive tumors (lung, liver, esophageal, kidney or adrenocortical).

The company said it plans to begin studies of ADH-1 in combination with other anticancer agents, such as chemotherapy, radiation therapy or biologics, in mid-2006.

Adherex is a biopharmaceutical company dedicated to the development of novel cancer therapeutics based in Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.